newsfilter
← Latest News
GlobeNewswire·

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML